An Omicron-specific booster could be ready by August, the CEO of US biotech firm Moderna told Reuters, but the firm is still gathering clinical data to determine whether that vaccine would offer better protection than a new dose of the existing jab.

Last month, Moderna began clinical trials for a booster dose specifically designed to target Omicron but initial results from studies in monkeys show the Omicron-specific shot may not offer stronger protection than a new dose of the existing vaccine.

Moderna chief executive Stephane Bancel said...